HARP / Harpoon Therapeutics to Present Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023

Harpoon Therapeutics Inc shares surged as much as 40% in pre-market trading on Monday after the clinical-stage immunotherapy company announced that it more_horizontal

SOUTH SAN FRANCISCO, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company deve more_horizontal

KOLs to provide insight and discussion of HPN328 targeting SCLC, NEPC and other neuroendocrine tumors Abstract with HPN328 interim data accepted for p more_horizontal

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Harpoon Therapeutics, Inc. (HARP) more_horizontal

Harpoon Therapeutics offers an example of biotech's volatility. The stock advanced as much as 191% intraday Monday before settling down to a gain of 2 more_horizontal

Updated interim results from Phase 1 clinical trial of HPN217 in heavily pretreated patients with relapsed/refractory multiple myeloma to be presented more_horizontal

Harpoon Therapeutics is an oncology platform play developing tri-specific drug candidates. The company's lead candidates HPN217 and HPN328 are in Phas more_horizontal

Harpoon Therapeutics, Inc. (HARP) delivered earnings and revenue surprises of 3.64% and 9.95%, respectively, for the quarter ended June 2022. Do the n more_horizontal